Breaking News
July 22, 2018 - Survey results identify major inequalities in acute stroke treatment across Europe
July 22, 2018 - Researchers discover promising treatment for genetic form of autism spectrum disorder
July 22, 2018 - Prenatal Depression More Common in Young Moms Today
July 22, 2018 - What helps adults with autism get and keep a job?
July 22, 2018 - Pediatric NEXUS Head CT DI guides selective imaging decisions in blunt trauma patients
July 22, 2018 - Novel tool predicts genes that cause disease due to production of truncated proteins
July 22, 2018 - AHA: Vaping Tied to Blood Clots — in Mice
July 22, 2018 - Study finds therapy dogs effective in reducing symptoms of ADHD
July 22, 2018 - Scientists find reason why malarial parasites are faster than immune cells
July 22, 2018 - Researchers gain more insight into how FUS protein causes ALS and FTLD
July 22, 2018 - Frequency of joint replacements halved in rheumatoid arthritis patients between 1997-2010
July 22, 2018 - QUT researcher highlights growing impact of non-prescription antibiotics supply in pharmacies
July 22, 2018 - UK health communication researcher seeks solutions for disposing leftover medicine
July 22, 2018 - Pfizer Initiates Pivotal Phase 3 Program for Investigational Hemophilia B Gene Therapy Fidanacogene Elaparvovec
July 22, 2018 - Mutation discovered to protect against Alzheimer’s disease in mice
July 22, 2018 - Researchers reveal how patients in urban areas develop multiple, long-term conditions
July 22, 2018 - Replacing conventional cancer treatment with complementary therapy linked to increased risk of death
July 22, 2018 - Study uncovers molecular key for delaying progression of multiple sclerosis
July 22, 2018 - Availability of athletic trainer in high school reduces injury rates in girls’ sports, shows study
July 22, 2018 - FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria
July 22, 2018 - Novel nuclear medicine probe will help assess new drugs for neurodegenerative diseases
July 22, 2018 - Physical activity even during exposure to air pollution can reduce risk of heart attack
July 22, 2018 - Scientists discover protein regulator of myelin production
July 22, 2018 - Sleep disturbances associated with higher dementia risk
July 22, 2018 - Scientists move one step further in developing eye drops to treat age-related macular degeneration
July 22, 2018 - Five-Year Stroke Rates Lower After PCI Versus CABG
July 21, 2018 - Alopecia areata – Genetics Home Reference
July 21, 2018 - Study identifies overdose risk factors in youth with substance use disorders
July 21, 2018 - Drug in clinical trials for Parkinson’s disease offers hope for treating heart failure
July 21, 2018 - Coupling free malaria tests with diagnosis-dependent vouchers can improve rational use of ACTs
July 21, 2018 - Sweetness depends on molecular interactions between specific sugars and water in saliva
July 21, 2018 - Muscle fitness is strongly associated with improved rate of ageing in the brain
July 21, 2018 - Resetting E-Prescriptions for Opioids Helps Curb Use: Study
July 21, 2018 - Overuse of antibiotics not what the doctor ordered
July 21, 2018 - Bundled-payment system did not lower costs for serious medical conditions, shows study
July 21, 2018 - Therapy dogs found to be effective in reducing ADHD symptoms in children
July 21, 2018 - Could rotating multiple therapists better treat PTSD patients?
July 21, 2018 - Binge drinking impairs working memory in adolescent brain
July 21, 2018 - Dying at home could be beneficial for terminally ill cancer patients and their relatives
July 21, 2018 - Researchers identify subtypes of retinal ganglion cells using single-cell RNA sequencing
July 21, 2018 - Study uncovers opportunities to reduce death by suicide among cancer patients
July 21, 2018 - Genetic sequencing reveals new clues to aggressiveness of prostate cancer
July 21, 2018 - BioSight Launches a Phase 2b Clinical Trial of BST-236 as a First-Line Treatment of Acute Myeloid Leukemia
July 21, 2018 - First major study comparing robotic to open surgery published in The Lancet
July 21, 2018 - ADHD medications may fail to improve cognition in healthy college students, study shows
July 21, 2018 - Intervention program that includes a personalized app could benefit teens with suicidal thoughts
July 21, 2018 - Researchers identify new compound that protects against neurodegeneration
July 21, 2018 - Gene therapy may hold potential to treat people with spinal cord injuries
July 21, 2018 - FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
July 21, 2018 - Surgeons have substantial impact on genetic testing in breast cancer patients who need it
July 21, 2018 - Species diversity can have positive and negative impacts on disease transmission
July 21, 2018 - Genome research suggests presence of enteric fever in medieval Europe
July 21, 2018 - Risk of Sensory Deficits Drops With Rising Gestational Age
July 21, 2018 - Mum’s sleep matters—the effect of sleep on an unborn baby
July 21, 2018 - UC San Diego researchers awarded two grants for investigating stem cell-based therapies
July 21, 2018 - Cellular ‘garbage disposal’ may actually work on some of the proteins to neuronal development
July 21, 2018 - More Pregnant Women Having Heart Attacks
July 21, 2018 - Acne Breakouts | NIH News in Health
July 21, 2018 - Change health messaging to focus on potential impact to help stop the next pandemic
July 21, 2018 - Frailty associated with poor survival rates in young heart patients
July 21, 2018 - New discovery could save millions of lives from fatal fungal infections
July 21, 2018 - OBD presents latest data on the use of EpiSwitch™ in predicting patient response to immunotherapy and identifying lymphoma subtypes
July 21, 2018 - Childhood adversity increases susceptibility to addiction via immune response
July 21, 2018 - Scientists identify potential target for the treatment of binge eating
July 21, 2018 - Whole-brain LIPUS therapy improves cognitive dysfunction in mice simulating dementia, Alzheimer’s
July 21, 2018 - Digital media use raising risk of ADHD symptoms among the young
July 21, 2018 - Phase 3 study of tanezumab in patients with osteoarthritis pain meets all three co-primary endpoints
July 21, 2018 - Restoring mitochondrial function to reverse aging-related skin wrinkles, hair loss in mice
July 21, 2018 - SP PennTech introduces RW-500 rotary vial washer for biotech, pharmaceutical applications
July 21, 2018 - Researchers to study molecular mechanisms behind susceptibility of males to autism
July 21, 2018 - Using tendon transfer surgery to restore key functions in spinal cord injury patient
July 21, 2018 - Scientists create wearable device that measures cortisol in sweat
July 21, 2018 - Researchers study efficacy and safety of new treatment for OUD
July 21, 2018 - Fourth Published Clinical Trial Confirms Long-Term Safety of Niagen Supplementation at High Doses and Shows Potential for Improvement in Liver Health
July 21, 2018 - Study examines effects of a two-day intermittent calorie restriction diet for patients with type 2 diabetes
July 21, 2018 - Greening vacant urban land reduces feelings of depression for surrounding residents
July 21, 2018 - Parents say intense gun violence in PG-13 movies appropriate for teens 15 and older
July 21, 2018 - Collaborative study to assess effects of exercise training for cognitive deficits in MS
July 21, 2018 - FAU researchers find possible cause of Parkinson’s disease in the patients’ immune system
July 21, 2018 - Protective qualities of ‘good cholesterol’ reduce after menopause
Mechanism behind common Parkinson’s mutation discovered

Mechanism behind common Parkinson’s mutation discovered

image_pdfDownload PDFimage_print
Lipid reduction using an FDA-approved glucosylceramide synthase inhibitor (GCSi) reduces pathological alpha-synuclein in cell bodies (top) and neurites (bottom) of Parkinson’s patient neurons. Yellow staining indicates pathological alpha-synuclein. Credit: Northwestern University

Northwestern Medicine investigators have discovered how a gene mutation results in buildup of a toxic compound known to cause Parkinson’s disease symptoms, defining for the first time the mechanism underlying that aspect of the disease.

The study, published in Neuron, points to a potential novel therapeutic pathway using drugs originally intended to treat another condition, Gaucher’s disease, according to senior author Joseph Mazzulli, Ph.D., assistant professor in The Ken & Ruth Davee Department of Neurology, Division of Movement Disorders.

In Parkinson’s, a protein called alpha-synuclein is converted to insoluble, toxic clusters in the central nervous system—but the exact mechanism of conversion was unknown until now.

One of the strongest risk factors for developing these clusters is a mutation in the gene GBA1, which normally degrades a lipid called glucosylceramide. Patients with one mutation in the gene suffer an increased level of glucosylceramide and have been shown to have a five-fold increased risk for Parkinson’s; patients with two mutant forms of the gene, one inherited from each parent, can develop Gaucher’s disease, a lysosomal storage disorder.

Mazzulli and his colleagues used this genetic connection to elucidate the mechanism of GBA1-influenced Parkinson’s disease. Using stem cell models of neurons, they used a pharmacological inhibitor to increase levels of glucosylceramide without a mutated GBA1 gene. Even without the mutation, this resulted in a dramatic build-up of toxic alpha-synuclein in neurons.

“This suggested to us that the critical factor in converting alpha-synuclein from its normal form to its pathogenic form was not necessarily the presence of the mutated GBA1 protein, but more importantly the decreased activity and accumulation of glucosylceramide,” Mazzulli said.

With that realization in mind, the investigators took a closer look at the conversion process, finding the healthy form of alpha-synuclein actually existed in two different forms, a simple molecule and a more complex molecule. While it was assumed previously that only the simple molecule was converted into the toxic variety, Mazzulli and his colleagues unexpectedly found the complex molecule was directly converted by glucosylceramide into toxic alpha-synuclein.

“We were surprised to find that toxic aggregation occurred by direct conversion of the large alpha-synuclein complex,” Mazzulli said. “We thought the complex would have to first disassemble before forming toxic aggregates, but that’s not what our data indicated.”

These discoveries suggest that future therapies targeting this pathway might utilize drugs originally intended for treating Gaucher’s disease, Mazzulli said. While the pharmaceutical industry has been interested in the use of those lipid-reducing agents for some time, this study defines the molecular process behind those efforts and demonstrates how it might work.

“Some companies have been using synthase inhibitors to reduce the synthesis of the lipid, and we used a similar compound on patient-derived neurons in our study,” Mazzulli said. “We were able to show it reduced toxic alpha-synuclein aggregation directly within neurons derived from Parkinson’s patients.”

In addition, the study gives future drug trials an important metric to measure success, Mazzulli said.

“Our ultimate goal is to reduce alpha-synuclein levels in patients, however measuring the levels of alpha synuclein from the central nervous system of a living patient is complicated,” Mazzulli said. “It’s far easier to measure the effects of therapeutics that alter glucosylceramide in patients, since the lipid can be directly measured from easily accessible fluids, such as blood or cerebral spinal fluid.”

The next step towards a functional treatment will be to graduate from stem cell-derived neurons to animal models, according to Mazzulli.

“We’re trying to determine if this occurs in a living animal and if we can reverse it using similar compounds to what’s being tested in these clinical trials,” Mazzulli said. “If we can intervene before any insoluble amyloid protein develops, maybe we can reverse it to its normal state.”


Explore further:
Tug of war between Parkinson’s protein and growth factor

Journal reference:
Neuron

Provided by:
Northwestern University

Tagged with:

About author

Related Articles